SARS-CoV-2 Omicron neutralization by therapeutic antibodies, convalescent sera, and post-mRNA vaccine booster

Sabrina Lusvarghi,Simon D. Pollett,Sabari Nath Neerukonda,Wei Wang,Richard Wang,Russell Vassell,Nusrat J. Epsi,Anthony C Fries,Brian K Agan,David A. Lindholm,Christopher J. Colombo,Rupal Mody,Evan C. Ewers,Tahaniyat Lalani,Anuradha Ganesan,Emilie Goguet,Monique Hollis-Perry,Si’Ana A. Coggins,Mark P. Simons,Leah C. Katzelnick,Gregory Wang,David R. Tribble,Lisa Bentley,Ann E. Eakin,Christopher C. Broder,Karl J. Erlandson,Eric D. Laing,Timothy H. Burgess,Edward Mitre,Carol D. Weiss

DOI: https://doi.org/10.1101/2021.12.22.473880

IF: 17.1

2021-01-01

Science Translational Medicine

Abstract:The rapid spread of the highly contagious Omicron variant of SARS-CoV-2 along with its high number of mutations in the spike gene has raised alarm about the effectiveness of current medical countermeasures. To address this concern, we measured neutralizing antibodies against Omicron in three important settings: (1) post-vaccination sera after two and three immunizations with the Pfizer/BNT162b2 vaccine, (2) convalescent sera from unvaccinated individuals infected by different variants, and (3) clinical-stage therapeutic antibodies. Using a pseudovirus neutralization assay, we found that titers against Omicron were low or undetectable after two immunizations and in most convalescent sera. A booster vaccination significantly increased titers against Omicron to levels comparable to those seen against the ancestral (D614G) variant after two immunizations. Neither age nor sex were associated with differences in post-vaccination antibody responses. Only three of 24 therapeutic antibodies tested retained their full potency against Omicron and high-level resistance was seen against fifteen. These findings underscore the potential benefit of booster mRNA vaccines for protection against Omicron and the need for additional therapeutic antibodies that are more robust to highly mutated variants. One Sentence Summary Third dose of Pfizer/BioNTech COVID-19 vaccine significantly boosts neutralizing antibodies to the Omicron variant compared to a second dose, while neutralization of Omicron by convalescent sera, two-dose vaccine-elicited sera, or therapeutic antibodies is variable and often low. ### Competing Interest Statement Simon D. Pollett., Timothy H. Burgess, and David R.Tribble report that the Uniformed Services University (USU) Infectious Diseases Clinical Research Program (IDCRP), a US Department of Defense institution, and the Henry M. Jackson Foundation (HJF) were funded under a Cooperative Research and Development Agreement to conduct an unrelated phase III COVID-19 monoclonal antibody immunoprophylaxis trial sponsored by AstraZeneca. The HJF, in support of the USU IDCRP, was funded by the Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense to augment the conduct of an unrelated phase III vaccine trial sponsored by AstraZeneca. Both of these trials were part of the US Government COVID-19 response.